Akeso’s novel AS drug Gumokimab accepted for review by China’s drug regulator

This marks the second indication for which gumokimab has gained NDA review acceptance

Alto Neuroscience bags new US patent for depression drug ALTO-207

ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease

China nod to two Sanofi drugs for rare and complex conditions

Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM

China nod to first homegrown BNCT cancer drug for human trials

The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials

DNA Nanorobots & AI could slash drug development times, Nanovery CEO says

DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours

IRLAB Therapeutics teams up with Biomia to advance novel CNS drug candidates

Redesigned brain receptor drugs show promise for depression

The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold

Gabby Union-Wade fronts Bayer's new menopause drug, Lynkuet

The collaboration centers on the "Life Doesn't Stop for a Hot Flash" campaign

FDA finds no clear link between popular diabetes, weight-loss drugs and suicidal thoughts

The FDA also noted that current prescribing information for GLP-1 RAs already includes warnings about the risk of suicidal thoughts

EMA and FDA unveil joint AI principles to transform drug revelopment

Experts caution that realizing AI’s potential requires careful management and risk mitigation